Team

Christine Lacabaratz is a PhD. As post-doctoral fellow, she has contributed to describe longitudinal CD4 and CD8 T cell responses in acutely HIV-infected patients and in HIV controllers. She then joined the Inserm U955/Team 16/Vaccine Research Institute (VRI) directed by Pr. Yves Lévy and has a permanent position at the University Paris 12 since 2008. Untill 2023, she was the head of the Mondor immunomonitoring center (MIC) where she developed innovative technologies to perform key end-point immune assays to evaluate human immune responses in many immunotherapeutic and prophylactic vaccine clinical trials. She was workpackage leader of 2 vaccine trials on Ebola in France and Africa and co-investigator of a study on Ebola survivors in Guinea. Since the COVID-19 outbreak in France, she has been involved in the immunological studies of SARS-CoV-2 infected subjects included in differents cohorts and vaccine trials in Europe and Africa. Since 2023, she joigned the DC-based vaccines Division developing innovative preventive and therapeutic vaccine candidates targeting dendritic cells against emerging and re-emerging infectious diseases. She is actually principal investigator of a new vaccine against Mycobacterium tuberculosis and is the coordinator of an ANR project « DC-TBVac » (ANR2022-CE17-0024) for the generation of a new tuberculosis vaccine potentially to limit both the risk of secondary transmission during treatment in tuberculosis-infected subjects and treatment toxicity, and overall, to prevent activation of tuberculosis disease in latently-infected individuals.